ALS2 and amyotrophic lateral sclerosis: In conformity, based on data from previous experiments, and having the opportunity to work with astrocytes differentiated from ALS patient somatic cells, we anticipated that the pre-miR-146a treatment in the mSOD1-ALS2 and sALS7 iAstrocytes would modulate their secretome-mediated toxicity to MNs.